29,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
As the first 1-year, multinational, double-blinded, placebo-controlled study of a cholinesterase inhibitor in AD, these data support donepezil as a well tolerated and effective long-term treatment for patients with AD, with benefits over placebo on global assessment, cognition, and ADL. 3 key findings →
Participants: 286 Evidence: high
Full summary, score breakdown and related studies → Original source
Intelligence is highly heritable 1 and a major determinant of human health and well-being 2 . 2 key findings →
Design: meta-analysis Participants: 269,867 Evidence: high
Full summary, score breakdown and related studies → Original source
Collecting cases for case-control genetic association studies can be time-consuming and expensive. 1 key finding →
Design: meta-analysis Participants: 116,196 Evidence: high
Full summary, score breakdown and related studies → Original source
Due to the small number of studies and heterogeneity in study design and outcomes, the association between DNA methylation age and age-related disease and longevity is inconclusive. 3 key findings →
Design: systematic review Participants: 41,607 Evidence: high
Full summary, score breakdown and related studies → Original source
Immunotherapeutics targeting amyloid-β (Aβ) have had mixed results in clinical trials. 3 key findings →
Participants: 5,554 Evidence: high
Full summary, score breakdown and related studies → Original source
The efficacy and safety of anti-amyloid mAbs in AD may differ based on patients' demographic and genetic factors. 4 key findings →
Design: systematic review Participants: 5,633 Evidence: high
Full summary, score breakdown and related studies → Original source
ACHIEVE-P sets the stage for the full-scale ACHIEVE trial (N = 850, recruitment beginning November 2017), the first randomized trial to determine efficacy of a best practices hearing (vs. successful aging) intervention on reducing cognitive decline in older adults with HL. 1 key finding →
Design: randomized controlled trial Participants: 850 Evidence: high
Full summary, score breakdown and related studies → Original source
Regarding exposures to air pollution, there was convincing (class I) evidence for the association between long-term exposure to solvents and a higher incidence of dementia or cognitive impairment (odds ratio, OR=1.139), and highly suggestive (class II) evidence for the association between long-term exposure to some pollutants and higher risk for cognitive disorders (higher incidence of dementia with high vs. low levels of carbon monoxide, CO: OR=1.587; higher incidence of vascular dementia per 1 μg/m 3 increase of nitrogen oxides, NO x : hazard ratio, HR=1.004). 1 key finding →
Design: systematic review Participants: 195 Evidence: high
Full summary, score breakdown and related studies → Original source
A total of 210 participants were enrolled and 82% completed 26 weeks of treatment. 5 key findings →
Design: clinical trial Participants: 210 Evidence: high
Full summary, score breakdown and related studies → Original source
More than 25% of the U.S. population aged ≥ 65 years has diabetes mellitus (hereafter referred to as diabetes),1 and the aging of the overall population is a significant driver of the diabetes epidemic. 5 key findings →
Design: meta-analysis Participants: 1,000 Evidence: high
Full summary, score breakdown and related studies → Original source
Plasma Aβ40 values might not distinguish between PET (+) and PET (-) people. 2 key findings →
Design: meta-analysis Participants: 3,047 Evidence: high
Full summary, score breakdown and related studies → Original source
To assess for potential differences in cognitive test scoring when using a remote platform, and where a remote screener was compared to the equivalent face-to-face test. 4 key findings →
Design: meta-analysis Participants: 3,075 Evidence: high
Full summary, score breakdown and related studies → Original source
This study has the potential to provide the first evidence of the effectiveness of information communication technology and Internet of Things in incident dementia. 1 key finding →
Design: randomized controlled trial Participants: 1,749 Evidence: high
Full summary, score breakdown and related studies → Original source
Our preliminary findings suggest that web-based cognitive training programs may benefit African Americans with MCI at least as much as Caucasians, and highlight the need to further study underrepresented minorities in AD prevention trials. 5 key findings →
Design: randomized controlled trial Participants: 105 Evidence: high
Full summary, score breakdown and related studies → Original source
The genetic basis of Alzheimer's disease (AD) is complex and heterogeneous. 4 key findings →
Design: meta-analysis Participants: 3,500 Evidence: high
Full summary, score breakdown and related studies → Original source
In this meta-analysis of the association of physical activity with cognitive decline, physical activity was associated with better late-life cognition, but the association was weak. 5 key findings →
Design: meta-analysis Participants: 341,471 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The first single-stage individual patient data meta-analysis from randomized double-blind placebo-controlled clinical trials provides evidence to support benefits of antihypertensive treatment in late-mid and later life to lower the risk of dementia. 5 key findings →
Design: meta-analysis Participants: 28,008 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
An unresolved question for the understanding of Alzheimer's disease (AD) pathophysiology is why a significant percentage of amyloid-β (Aβ)-positive cognitively unimpaired (CU) individuals do not develop detectable downstream tau pathology and, consequently, clinical deterioration. 5 key findings →
Design: cohort Participants: 1,016 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In this study of adults with subjective memory impairment, a 6-month program of physical activity provided a modest improvement in cognition over an 18-month follow-up period. 3 key findings →
Design: randomized controlled trial Participants: 170 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Epidemiological studies suggest that consumption of DHA is associated with a reduced incidence of Alzheimer disease. 5 key findings →
Participants: 102 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Tarenflurbil did not slow cognitive decline or the loss of activities of daily living in patients with mild AD. 3 key findings →
Design: clinical trial Participants: 1,684 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Memantine is a moderate affinity uncompetitive antagonist of glutamate NMDA receptors. 4 key findings →
Design: post-hoc analysis Participants: 10,000 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
We identified 22 hospital-based and eight population-based eligible cohorts (7511 patients) described in 73 papers. 2 key findings →
Design: systematic review Participants: 7,511 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53). 3 key findings →
Participants: 8,506 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The global prevalence of MCI among community dwellers is over 15% and is affected by age, gender, education level and region of study sites. 4 key findings →
Design: systematic review Participants: 242,804 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 29,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 29,380 records, built mostly from automated pulls of Europe PMC (63.3% of the library) and OpenAlex (17.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,037 records (3.5% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →